Form Type: 4

SEC EDGAR Link
Acccession Number:0001140361-19-009199
Date:2019-05-14
Issuer: ALLOGENE THERAPEUTICS, INC. (ALLO)
Original Submission Date:

Reporting Person:

TPG GROUP HOLDINGS (SBS) ADVISORS, INC.
C/O TPG GLOBAL, LLC
301 COMMERCE STREET, SUITE 3300 FORT WORTH, TX 76102

Reporting Person:

BONDERMAN DAVID
C/O TPG GLOBAL, LLC
301 COMMERCE STREET, SUITE 3300 FORT WORTH, TX 76102

Reporting Person:

COULTER JAMES G
C/O TPG GLOBAL, LLC
301 COMMERCE STREET, SUITE 3300 FORT WORTH, TX 76102

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-05-14 S 1,918,755 d $29.38 21,216,306 indirect f1,f2,f3,f4
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 david bonderman and james g. coulter are the sole shareholders of tpg group holdings (sbs) advisors, inc. (together with messrs. bonderman and coulter, the "reporting persons"), which is the sole member of tpg group holdings (sbs) advisors, llc, which is the general partner of tpg group holdings (sbs), l.p., which is the sole member of tpg holdings i-a, llc, which is the general partner of tpg holdings i, l.p., which is the sole member of each of (i) tpg genpar vii advisors, llc and (ii) the rise fund genpar advisors, llc. tpg genpar vii advisors, llc is the general partner of tpg genpar vii, l.p., which is the general partner of tpg carthage holdings, l.p., which directly holds 14,144,202 shares of common stock ("common stock") of allogene therapeutics, inc.
f2 the rise fund genpar advisors, llc is the general partner of the rise fund genpar, l.p., which is the general partner of the rise fund carthage, l.p. (together with tpg carthage holdings, l.p., the "tpg funds"), which directly holds 7,072,104 shares of common stock.
f3 because of the relationship between the reporting persons and the tpg funds, the reporting persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the tpg funds. each tpg fund and each reporting person disclaims beneficial ownership of the securities reported herein, except to the extent of such tpg fund's or such reporting person's pecuniary interest therein, if any.
f4 pursuant to rule 16a-1(a)(4) under the securities exchange act of 1934, as amended (the "exchange act"), this filing shall not be deemed an admission that the reporting persons are, for purposes of section 16 of the exchange act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Elevate your investments